DR info

Clinical trials : 147 / Drugs : 176 - (DrugBank : 43) / Drug target genes : 49 - Drug target pathways : 110

Drugs and their primary sponsors and trial info

100 µg Brimonidine Tartrate Implant
   Allergan
      2008   Phase 1/Phase 2   NCT00661479   France;Germany;Portugal;United States;
200 µg Brimonidine Tartrate Implant
   Allergan
      2008   Phase 1/Phase 2   NCT00661479   France;Germany;Portugal;United States;
400 µg Brimonidine Tartrate Implant
   Allergan
      2008   Phase 1/Phase 2   NCT00661479   France;Germany;Portugal;United States;
4D-125 IVT Injection
   4D Molecular Therapeutics
      2020   Phase 1/Phase 2   NCT04517149   United States;
9715X
   Allergan Limited
      2010   -   EUCTR2010-019079-32-PT   Czech Republic;Germany;Italy;Portugal;United Kingdom;
      2010   -   EUCTR2010-019079-32-DE   Czech Republic;Germany;Italy;Portugal;United Kingdom;
9741X
   Allergan Limited
      2010   -   EUCTR2010-019079-32-PT   Czech Republic;Germany;Italy;Portugal;United Kingdom;
      2010   -   EUCTR2010-019079-32-DE   Czech Republic;Germany;Italy;Portugal;United Kingdom;
9742X
   Allergan Limited
      2010   -   EUCTR2010-019079-32-PT   Czech Republic;Germany;Italy;Portugal;United Kingdom;
      2010   -   EUCTR2010-019079-32-DE   Czech Republic;Germany;Italy;Portugal;United Kingdom;
AAV-RPGR
   MeiraGTx UK II Ltd
      2019   -   NCT04312672   United Kingdom;
AAV2-REP1
   NightstaRx Ltd
      2018   Phase 3   EUCTR2017-003104-42-GB   Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States;
   NightstaRx Ltd (A Biogen Company)
      2021   Phase 3   EUCTR2017-003104-42-DK   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003104-42-FI   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003104-42-DE   Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States;
AAV2/5-hPDE6B
   Coave Therapeutics
      2017   Phase 1/Phase 2   NCT03328130   France;
AAV2/5-hRKp.RPGR
   MeiraGTx UK II Limited
      2017   Phase 1;Phase 2   EUCTR2016-003967-21-GB   United Kingdom;United States;
   MeiraGTx UK II Ltd
      2018   Phase 1;Phase 2   EUCTR2018-000425-31-GB   United Kingdom;United States;
AAV5-RPGR
   MeiraGTx UK II Ltd
      2021   Phase 3   NCT04671433   United States;
AAV5-RPGR 2e11
   MeiraGTx UK II Ltd
      2021   Phase 3   NCT04794101   United States;
AAV5-RPGR 4e11
   MeiraGTx UK II Ltd
      2021   Phase 3   NCT04794101   United States;
AAV5-hRKp.RPGR
   MeiraGTx UK II Limited
      2022   Phase 3   EUCTR2020-002873-88-NL   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-002255-37-NL   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
AAV8-RPGR
   NightstaRx Limited
      2017   Phase 1;Phase 2;Phase 3   EUCTR2016-003852-60-GB   United Kingdom;United States;
   NightstaRx Ltd
      2018   Phase 3   EUCTR2017-003104-42-GB   Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States;
   NightstaRx Ltd (A Biogen Company)
      2021   Phase 3   EUCTR2017-003104-42-DK   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003104-42-FI   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003104-42-DE   Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States;
ALLOGENEIC NEURAL RETINA-DERIVED HUMAN NEURAL RETINAL PROGENITOR CELLS EX VIVO EXPANDED
   ReNeuron Ltd
      2020   Phase 2   EUCTR2019-004547-77-GB   United Kingdom;United States;
Acetazolamide
   Kyushu University Hospital
      2016   -   JPRN-UMIN000022686   Japan;
Adeno-associated virus type 2 vector encoding Rab escort protein 1
   NightstaRx Ltd (A Biogen Company)
      2021   Phase 3   EUCTR2017-003104-42-DK   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003104-42-FI   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003104-42-DE   Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States;
Aflibercept
   Moorfields Eye Hospital
      2016   Phase 2   EUCTR2015-003723-65-GB   United Kingdom;
   Moorfields Eye Hospital NHS Foundation Trust
      2016   Phase 2   NCT02661711   United Kingdom;
Alga Dunaliella Bardawil
   Sheba Medical Center
      2012   Phase 2/Phase 3   NCT01680510   Israel;
      2008   -   NCT01256697   Israel;
Alga Dunaliella Bardawil powder
   Sheba Medical Center
      2021   Phase 1/Phase 2   NCT02018692   Israel;
Alga Dunaliella Bardawill
   Sheba Medical Center
      2008   -   NCT01256697   Israel;
AlloRx
   The Foundation for Orthopaedics and Regenerative Medicine
      2022   Phase 1   NCT05147701   Antigua and Barbuda;
Antioxidants
   University of Colorado, Denver
      2008   Phase 2   NCT01773278   United States;
BIIB112
   NightstaRx Ltd, a Biogen Company
      2017   Phase 1/Phase 2   NCT03116113   United Kingdom;United States;
BMMNCs
   Chaitanya Hospital, Pune
      2014   Phase 1/Phase 2   NCT01914913   India;
BS01
   Bionic Sight LLC
      2020   Phase 1/Phase 2   NCT04278131   United States;
Betamethasone
   Kyushu University Hospital
      2016   -   JPRN-UMIN000022686   Japan;
Blue light-absorbing sunglasses
   Sun Yat-sen University
      2015   Phase 0   NCT02465749   China;
Botaretigene sparoparvovec
   MeiraGTx UK II Limited
      2022   Phase 3   EUCTR2020-002873-88-NL   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-002873-88-DK   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-002255-37-NL   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
      2022   Phase 3   EUCTR2020-002255-37-DK   Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;United States;
Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System
   Allergan Limited
      2010   -   EUCTR2010-019079-32-PT   Czech Republic;Germany;Italy;Portugal;United Kingdom;
      2010   -   EUCTR2010-019079-32-DE   Czech Republic;Germany;Italy;Portugal;United Kingdom;
CD34+ bone marrow stem cells intravitreal
   University of California, Davis
      2012   Phase 1   NCT01736059   United States;
CIRCADIN 2 mg comprimidos de liberación prolongada
   Isabel Pinilla Lozano
      2012   -   EUCTR2012-002436-82-ES   Spain;
CNS10-NPC implantation
   Cedars-Sinai Medical Center
      2021   Phase 1   NCT04284293   United States;
CNTO 2476
   Centocor, Inc.
      2007   Phase 1   NCT00458575   United States;
COQUN
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2009   -   EUCTR2008-004561-26-IT   Italy;
CPK850
   Novartis Pharmaceuticals
      2018   Phase 1/Phase 2   NCT03374657   Sweden;
Cannabis
   Hadassah Medical Organization
      2018   Early Phase 1   NCT03078309   Israel;
Cholesterol
   University of Colorado, Denver
      2008   Phase 2   NCT01773278   United States;
Ciliary Neurotrophic Factor Implant NT-501
   National Eye Institute (NEI)
      2003   Phase 1   NCT00063765   United States;
Combination Product: PRP combined Magnovision
   Ankara Universitesi Teknokent
      2017   -   NCT04252534   -
Compound thrombosis capsule sig: 1.5g/tid
   Sun Yat-sen University
      2015   Phase 0   NCT02465749   China;
Conditioned Medium (CM)
   PT. Prodia Stem Cell Indonesia
      2018   Phase 1/Phase 2   NCT04315025   Indonesia;
Continuous oxygen
   Sun Yat-sen University
      2015   Phase 0   NCT02465749   China;
Cornstarch control
   National Eye Institute (NEI)
      2003   Phase 3   NCT00346333   United States;
Cotoretigene Toliparvovec
   NightstaRx Ltd (A Biogen Company)
      2021   Phase 3   EUCTR2017-003104-42-DK   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003104-42-FI   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States;
Dexamethasone injection
   Rafic Hariri University Hospital
      2015   Phase 2   NCT02804360   -
Docosahexaenoic acid
   Retina Foundation of the Southwest
      2004   Phase 2   NCT00100230   United States;
      1996   -   NCT00004827   -
Dorzolamide
   Kyushu University Hospital
      2016   -   JPRN-UMIN000022686   Japan;
   Kyushu university hospital
      2010   -   JPRN-UMIN000005852   Japan;
Eylea
   Moorfields Eye Hospital
      2016   Phase 2   EUCTR2015-003723-65-GB   United Kingdom;
GS030-DP
   GENSIGHT-BIOLOGICS
      2017   Phase 1;Phase 2   EUCTR2017-002204-27-GB   United Kingdom;United States;
Gene Therapy Product-vMCO-010
   Nanoscope Therapeutics Inc.
      2021   Phase 2   NCT04945772   Puerto Rico;United States;
Gene Therapy product:vMCO-I
   Nanoscope Therapeutics Inc.
      2019   Phase 1/Phase 2   NCT04919473   India;
Ginkgo biloba pills sig: 300mg/tid
   Sun Yat-sen University
      2015   Phase 0   NCT02465749   China;
HORA-PDE6B (AAV2/5.hPDE6B)
   HORAMA SA
      2017   Phase 1;Phase 2   EUCTR2016-001429-16-FR   France;
HRPC
   ReNeuron Limited
      2015   Phase 1/Phase 2   NCT02464436   Spain;United Kingdom;United States;
HRPC DP
   ReNeuron Ltd
      2020   Phase 2   EUCTR2019-004547-77-GB   United Kingdom;United States;
Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)
   Centre d'Etude des Cellules Souches
      2019   Phase 1/Phase 2   NCT03963154   France;
Human Retinal Progenitor Cells Drug Product
   ReNeuron Ltd
      2020   Phase 2   EUCTR2019-004547-77-GB   United Kingdom;United States;
Human primary Retinal Pigment Epithelial (HuRPE) cells
   Eyecure Therapeutics Inc.
      2018   Early Phase 1   NCT03566147   China;
Human retinal progenitor cells
   jCyte, Inc
      2020   Phase 2   NCT04604899   United States;
      2017   Phase 2   NCT03073733   United States;
      2015   Phase 1/Phase 2   NCT02320812   United States;
Hydroxychloroquine higher dose
   University of Michigan
      2020   Phase 1/Phase 2   NCT04120883   United States;
Hydroxychloroquine lower dose
   University of Michigan
      2020   Phase 1/Phase 2   NCT04120883   United States;
Hyperbaric oxygen therapy
   Azienda Policlinico Umberto I
      2004   -   NCT00461435   Italy;
Iluvien
   Moorfields Eye Hospital
      2016   Phase 2   EUCTR2016-002523-28-GB   United Kingdom;
Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa
   Jinnah Burn and Reconstructive Surgery Centre, Lahore
      2021   Phase 2   NCT04763369   Pakistan;
Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa
   Jinnah Burn and Reconstructive Surgery Centre, Lahore
      2021   Phase 2   NCT04763369   Pakistan;
Intravitreal autologous CD34+ cells
   University of California, Davis
      2021   Phase 1   NCT04925687   United States;
Intravitreal injection of Autologous bone marrow Stem Cell
   Red de Terapia Celular
      2014   Phase 1   NCT02280135   Spain;
Intravitreal injection of autologous bone marrow stem cells
   University of Sao Paulo
      2011   Phase 2   NCT01560715   Brazil;
      2009   Phase 1   NCT01068561   Brazil;
KIO-301
   Kiora Pharmaceuticals, Inc.
      2022   Phase 1   NCT05282953   -
Lentiviral vector containing MYO7A gene
   sanofi-aventis recherche & développement
      2013   Phase 1;Phase 2   EUCTR2012-002574-31-FR   France;United States;
Lentiviral vector containing the human MY07A gene
   sanofi-aventis recherche & développement
      2013   Phase 1;Phase 2   EUCTR2012-002574-31-FR   France;United States;
Levodopa-carbidopa
   Beirut Eye Specialist Hospital
      2016   Phase 2   NCT02837640   Lebanon;
Lutein
   National Eye Institute (NEI)
      2003   Phase 3   NCT00346333   United States;
Lutein (10 or 30 mg/day) capsules
   National Center for Complementary and Integrative Health (NCCIH)
      2001   Phase 1/Phase 2   NCT00029289   United States;
Lycium Barbarum
   The Hong Kong Polytechnic University
      2014   -   NCT02244996   Hong Kong;
Minocycline
   National Eye Institute (NEI)
      2014   Phase 1/Phase 2   NCT02140164   United States;
   Sun Yat-sen University
      2019   Phase 2   NCT04068207   China;
N-Acetyl Cysteine (NAC)
   Johns Hopkins University
      2017   Phase 1   NCT03063021   United States;
NAC effervescent tablets
   Johns Hopkins University
      2019   Phase 1   NCT03999021   United States;
NPI-001
   Nacuity Pharmaceuticals, Inc.
      2020   Phase 1/Phase 2   NCT04355689   Australia;
NT-501
   Neurotech Pharmaceuticals
      2012   Phase 2   NCT01530659   United States;
      2007   Phase 2   NCT00447993   United States;
      2007   Phase 2   NCT00447980   United States;
Nerve Growt Factor - 2.5S
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2009   -   EUCTR2008-004561-26-IT   Italy;
Nilvadipine
   Department of Ophthalmology, Hirosaki University Graduate School of Medicine
      2001   Phase 2   JPRN-UMIN000007895   Japan;
Nutritional Supplement
   National Eye Institute (NEI)
      1996   Phase 3   NCT00000116   United States;
OCU400 High Dose
   Ocugen
      2022   Phase 1/Phase 2   NCT05203939   United States;
OCU400 Low Dose
   Ocugen
      2022   Phase 1/Phase 2   NCT05203939   United States;
OCU400 Mid Dose
   Ocugen
      2022   Phase 1/Phase 2   NCT05203939   United States;
Phosphate
   Kyushu University Hospital
      2016   -   JPRN-UMIN000022686   Japan;
Platelet rich plasma
   Ankara Universitesi Teknokent
      2016   -   NCT04238858   Turkey;
Prescribe N-acetylcysteine tablets
   Shahid Beheshti University of Medical Sciences
      2021   Phase 2   NCT04864496   Iran, Islamic Republic of;
QLT091001
   QLT Inc.
      2019   Phase 3   EUCTR2013-005393-22-NL   Brazil;Canada;Denmark;France;Germany;Netherlands;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2013-005393-22-DK   Brazil;Canada;Denmark;France;Germany;Netherlands;Switzerland;United Kingdom;United States;
      2012   Phase 1   NCT01543906   Canada;Ireland;
      2012   Phase 1   NCT01521793   Canada;Germany;Netherlands;United Kingdom;United States;
      2012   Phase 1   EUCTR2011-004214-42-GB   Canada;Germany;Netherlands;United Kingdom;United States;
      2012   -   EUCTR2011-004214-42-NL   Canada;Germany;Netherlands;United Kingdom;United States;
      2012   -   EUCTR2011-004214-42-DE   Canada;Germany;Netherlands;United Kingdom;United States;
      2009   Phase 1   NCT01014052   Canada;Germany;Netherlands;United Kingdom;United States;
QR-1123
   ProQR Therapeutics
      2019   Phase 1/Phase 2   NCT04123626   United States;
QR-421a
   ProQR Therapeutics
      2021   Phase 2/Phase 3   NCT05176717   United Kingdom;United States;
      2021   Phase 2/Phase 3   NCT05158296   United Kingdom;United States;
      2019   Phase 1;Phase 2   EUCTR2018-002433-38-FR   Belgium;Canada;France;United States;
      2019   Phase 1/Phase 2   NCT03780257   Belgium;Canada;France;United States;
   ProQR Therapeutics IV B.V.
      -   Phase 2;Phase 3   EUCTR2021-002729-74-NO   Brazil;Canada;European Union;Germany;Norway;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2021-002729-74-NL   Brazil;Canada;European Union;Germany;Netherlands;Norway;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2021-002729-74-DK   Brazil;Canada;Denmark;European Union;Germany;Netherlands;Norway;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2021-002728-19-NL   Brazil;Canada;European Union;Germany;Netherlands;Norway;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2021-002728-19-FR   Brazil;Canada;European Union;France;Germany;Netherlands;Norway;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2021-002728-19-DK   Brazil;Canada;Denmark;European Union;France;Germany;Netherlands;Norway;United Kingdom;United States;
RAAV.hPDE6A vector
   Universitätsklinikum Tübingen
      2019   Phase 1;Phase 2   EUCTR2016-003705-34-DE   Germany;
RAAV2tYF-GRK1-RPGR
   Applied Genetic Technologies Corp
      2018   Phase 1/Phase 2   NCT03316560   United States;
RAAV2tYF-GRK1-hRPGRco
   Applied Genetic Technologies Corp
      2021   Phase 2/Phase 3   NCT04850118   Israel;Netherlands;United States;
RECOMBINANT HUMAN NERVE GROWTH FACTOR (RHNGF)
   Ospedale San Raffaele di Milano
      2014   -   EUCTR2014-000385-22-IT   Italy;
RNA antisense oligonucleotide for intravitreal injection
   ProQR Therapeutics
      2021   Phase 2   NCT05085964   Canada;France;United States;
RST-001
   Allergan
      2015   Phase 1/Phase 2   NCT02556736   United States;
Recombinant adeno-associated viral vector serotype 2.7m8 containing the ChrimsonR-tdTomato gene
   GENSIGHT-BIOLOGICS
      2017   Phase 1;Phase 2   EUCTR2017-002204-27-GB   United Kingdom;United States;
Recombinant human Nerve Growth Factor (rhNGF)
   Ospedale San Raffaele di Milano
      2014   -   EUCTR2014-000385-22-IT   Italy;
Retinal pigment epitheliums transplantation
   Qi Zhou
      2020   Phase 1   NCT03944239   China;
RhNGF 180 µg/ml eye drops solution
   Dompé Farmaceutici S.p.A
      2014   Phase 1/Phase 2   NCT02110225   Italy;
   Ospedale San Raffaele
      2015   Phase 2   NCT02609165   Italy;
RhNGF 60 µg/ml eye drops solution
   Dompé Farmaceutici S.p.A
      2014   Phase 1/Phase 2   NCT02110225   Italy;
SAR421869
   Sanofi
      2012   Phase 1/Phase 2   NCT01505062   France;United States;
Sham
   Neurotech Pharmaceuticals
      2012   Phase 2   NCT01530659   United States;
Sham Injection
   Nanoscope Therapeutics Inc.
      2021   Phase 2   NCT04945772   Puerto Rico;United States;
Sildenafil
   Columbia University
      2014   Phase 2   NCT04356716   United States;
Sodium valproate
   Yasuhiko Hirami
      2010   -   JPRN-JMA-IIA00053   Japan;
Stem Cell Transplantation
   Stem Cells Arabia
      2014   Phase 1/Phase 2   NCT02709876   Jordan;
Stem/progenitor cells transplantation
   Pomeranian Medical University Szczecin
      2018   Phase 1   NCT03772938   Poland;
Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus
   King Khaled Eye Specialist Hospital
      2011   Phase 1   NCT01482195   Saudi Arabia;
Subretinal injection of rAAV.hPDE6A
   STZ eyetrial
      2019   Phase 1/Phase 2   NCT04611503   Germany;
Subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP)
   Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      2020   Phase 3   NCT04636853   Italy;
Timrepigene emparvovec
   NightstaRx Ltd
      2018   Phase 3   EUCTR2017-003104-42-GB   Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States;
   NightstaRx Ltd (A Biogen Company)
      2021   Phase 3   EUCTR2017-003104-42-DK   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003104-42-FI   Brazil;Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003104-42-DE   Canada;Denmark;Finland;France;Germany;Netherlands;United Kingdom;United States;
Tocoferol
   Department of Ophthalmology, Hirosaki University Graduate School of Medicine
      2001   Phase 2   JPRN-UMIN000007895   Japan;
Triamcinolone
   Kyushu University Hospital
      2016   -   JPRN-UMIN000022686   Japan;
Twice-daily dosage with cyclosporine-A eyedrops
   Semmelweis University
      2007   -   NCT00433277   Hungary;
UF-021
   R-Tech Ueno, Ltd.
      2013   Phase 3   NCT01786395   Japan;
UF-021 (isopropyl unoprostone)
   R-Tech Ueno, Ltd
      2008   Phase 2   JPRN-JapicCTI-090748   -
UF-021(isopropyl unoprostone)
   R-Tech Ueno, Ltd
      -   Phase 3   JPRN-JapicCTI-132079   -
Umbilical Cord Mesenchymal Stem Cell (UC-MSC)
   PT. Prodia Stem Cell Indonesia
      2018   Phase 1/Phase 2   NCT04315025   Indonesia;
Unoprostone
   Kyushu university hospital
      2009   -   JPRN-UMIN000006820   Japan;
UshStat (SAR421869)
   sanofi-aventis recherche & développement
      2013   Phase 1;Phase 2   EUCTR2012-002574-31-FR   France;United States;
VA
   Columbia University
      2014   Phase 2   NCT04356716   United States;
   Kyushu University Hospital
      2016   -   JPRN-UMIN000023618   Japan;
Vehicle eye drops
   Ospedale San Raffaele
      2015   Phase 2   NCT02609165   Italy;
Vitamin A
   National Eye Institute (NEI)
      2003   Phase 1   NCT00065455   United States;
      1996   Phase 3   NCT00000116   United States;
      1984   Phase 3   NCT00000114   -
Vitamin AD sig: 1 tablet/tid
   Sun Yat-sen University
      2015   Phase 0   NCT02465749   China;
Vitamin B sig: 10mg/tid
   Sun Yat-sen University
      2015   Phase 0   NCT02465749   China;
Vitamin E
   National Eye Institute (NEI)
      1984   Phase 3   NCT00000114   -
Wharton's jelly derived mesenchymal stem cell
   Ankara Universitesi Teknokent
      2019   Phase 3   NCT04224207   Turkey;